Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 43 / Monday, March 8, 2021 / Notices 3. Enhance the quality, utility, and clarity of the information to be collected; and 4. Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submissions of responses.
5. Assess information collection costs.

jbell on DSKJLSW7X2PROD with NOTICES

Proposed Project Gonococcal Isolate Surveillance Project OMB Control No. 09200307, Exp. 8/31/2021RevisionNational Center for HIV/AIDS, Viral Hepatitis, STD, TB Prevention NCHHSTP, Centers for Disease Control and Prevention CDC.
Background and Brief Description The Gonococcal Isolate Surveillance Project GISP was created in 1986 to monitor trends in antimicrobial susceptibilities of Neisseria gonorrhoeae strains in the United States. GISP
continues to be a collaboration between different branches of the CDCs Division of STD Prevention, selected regional laboratories and selected state/local public health departments and their associated STD specialty care clinics in the United States. National organizations, local jurisdictions and individuals use data collected in GISP
to understand, monitor, and prevent further transmission of antibiotic resistant strains of N. gonorrhoeae. Data from GISP are used to establish a scientific basis for the selection of gonococcal therapies and to allow proactive changes to treatment guidelines before widespread resistance and failures of treatment occur. To increase capacity to detect and monitor resistant gonorrhea and to improve the specificity of GISP, this revision is being submitted to include collection of remnant nucleic acid amplification test NAAT
specimens and updated data element options for treatment received based on the 2020 updated gonorrhea treatment recommendations.
GISP core surveillance activities sample <4% of reported male gonorrhea cases in the United States and are limited to urethral infections only. In 2018, enhanced GISP eGISP began sampling female genital endocervical and vaginal and male and female extragenital pharyngeal and rectal anatomic sites, in addition to the male genital site already sampled in GISP
core surveillance. Including isolates from the pharynx and other anatomic sites, as well as from women, expands
VerDate Sep<11>2014

19:05 Mar 05, 2021

Jkt 253001

on GISPs public health efforts to detect and respond to resistance more quickly.
GISP surveillance was also strengthened with the addition of eGISP by identifying isolates that are culture positive for N. gonorrhoeae, but negative by NAAT, which is a more specific diagnostic test. This helped to ensure that non-gonococcal bacteria are excluded from gonococcal data, strengthening the accuracy and usefulness of GISP data, especially when clinical syndromes with other Neisseria species are indistinguishable from gonorrhea.
To further improve and strengthen GISP surveillance, an additional enhanced surveillance activity in the form of molecular surveillance has been added to this revision. Participating sites already locally performing NAATs would retain the leftover gonorrheapositive samples remnant after diagnostic results have been determined and reported as part of standard care.
The gonorrhea-positive remnant NAAT
sample would be frozen, stored and then shipped directly to CDC on a monthly basis for molecular characterization of known resistanceconferring gene mutations. Remnant NAAT specimens from any anatomic site including from the urethra, pharynx, rectum, vagina and cervix of gonorrhea positive persons will be accepted. We anticipate that 10 sites will participate in this molecular surveillance activity and we anticipate up to 70 positive remnant NAAT
specimens per month will be sent by each of these 10 sites to CDC for testing.
To maintain accurate collection of GISP data elements, this revision also includes the updated weight-based dosing of ceftriaxone and cefixime. In December 2020, CDC released the Update to CDCs Treatment Guidelines for Gonococcal Infection. These new treatment recommendations increased the dose of the recommended regimen and the dose for an alternative regimen ceftriaxone and cefixime, respectively.
These values, collected and recorded under the received treatment data element, are being added to allow for the collection of treatment data consistent with these updated recommendations.
Under this revision, the data collection and processes for all GISP
activities are unchanged. The increased dosages for ceftriaxone and cefixime treatments allow for new data element options, but not a change in the number of data elements or the current work demand to collect them. All demographic/clinical data from the sentinel sites will be submitted
PO 00000

Frm 00117

Fmt 4703

Sfmt 4703

13395

electronically directly from the sentinel sites to the GISP data manager at CDC
through; 1 a secure data portal, or 2
through the CDC Secure Access Management Services partner portal. To minimize burden, comma-separated values csv files that provide standardized structure of the electronic data are provided to sentinel sites and laboratories. Additionally, to further minimize burden, the regional laboratories will be able to extract electronic data directly from electronic laboratory information systems instead of hand entering data. Laboratories are not required to report control strain testing results.
This project will not collect name, social security number, or date of birth.
A Patient ID, a unique patient identifier assigned by the site that allows for linking of multiple isolates from a single person at a single clinic visit and across multiple clinic visits, is requested and will be provided to CDC for purposes of enhanced surveillance. Sensitive information such as sex of sex partners, HIV status, sex work exposure, and injection drug use are collected. Patient data are obtained through review of medical records by the clinic staff and included in collection reporting of demographic/clinical information. All personally identifiable information PII
is retained by the STD clinics that treated the patient and is not recorded with data sent to CDC or regional laboratories. The electronic GISP
database is stored on the CDC
mainframe computer and only approved Division of STD Prevention DSTDP
staff have access rights to the data. As part of the revision, we will continue to systematically identify the risks and potential effects of collecting, maintaining, and disseminating PII and to examine and evaluate alternative processes for handling that information to mitigate potential privacy risks and risks to confidentiality.
The CDC has designated N.
gonorrhoeae as one of five urgent antibiotic resistance threats in the United States. The CDC is requesting a three-year OMB approval for this revision, which directly responds to the National Strategy for Combating Antibiotic Resistant Bacteria by improving and strengthening surveillance of antimicrobial resistance through GISP. GISP data can help monitor and evaluate the effectiveness of public health interventions conducted to support the National Strategy for Combating Antibiotic Resistant Bacteria. There are no costs to respondents other than their time.

E:FRFM08MRN1.SGM

08MRN1